Request Demo

Last update 08 May 2025

Baldness, Female Pattern

Last update 08 May 2025

Basic Info

Synonyms

Baldness, Female Pattern, Female Pattern Baldness, Female pattern alopecia

+ [9]

Introduction-

Drugs associated with Baldness, Female Pattern

OMA-102

Target-

Mechanism-

Active Org.

EMS SA (Brazil)

Originator Org.

EMS SA (Brazil)

Active Indication

Baldness, Female Pattern

Inactive Indication-

Drug Highest PhasePhase 3

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

DA-002

Target

CD49a

Mechanism

CD49a agonists

Active Org.

Applied Biology, Inc.

Originator Org.

Applied Biology, Inc.

Active Indication

Alopecia, Male Pattern [+2]

Inactive Indication-

Drug Highest PhasePhase 3

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Autologous cultured dermal and epidermal cells(Aderans Research Institute)

Target-

Mechanism-

Active Org.-

Originator Org.

Aderans Research Institute

Active Indication-

Inactive Indication

Alopecia, Male Pattern [+2]

Drug Highest PhasePending

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Clinical Trials associated with Baldness, Female Pattern

NCT06926023

/ Not yet recruitingNot ApplicableIIT

A Prospective, Randomized, Evaluator-blind, Clinical Trial Evaluating the 1550nm Non-ablative Fractional or 1927nm Thulium Fractional Laser for the Treatment of Female Pattern Hair Loss

To evaluate the efficacy of either a 1550nm non-ablative fractional laser or a 1927nm thulium fractional laser in the treatment of female pattern hair loss (FPHL).

Start Date01 May 2025

Sponsor / Collaborator-

TCTR20250312001

/ Not yet recruitingPhase 1/2IIT

EFFICACY AND SAFETY OF DIFFERENT CONCENTRATIONS OF TOPICAL FINASTERIDE ADMIXED WITH MINOXIDIL SOLUTION IN THE TREATMENT OF FEMALE PATTERN HAIR LOSS IN POSTMENOPAUSAL WOMEN: A PILOT STUDY

Start Date14 Mar 2025

Sponsor / Collaborator-

NCT06501924

/ Not yet recruitingPhase 3

Clinical Study of DA-002 and DA-005 As a Treatment for Hair Loss

The primary objective of the study is to assess the safety and efficacy of DA-005 and DA-002 as a treatment for hair loss (androgenetic alopecia).

Start Date15 Jan 2025

Sponsor / Collaborator

Applied Biology, Inc.

[+2]

100 Clinical Results associated with Baldness, Female Pattern

100 Translational Medicine associated with Baldness, Female Pattern

0 Patents (Medical) associated with Baldness, Female Pattern

Literatures (Medical) associated with Baldness, Female Pattern

03 Mar 2024·Expert Review of Endocrinology & Metabolism

An updated clinico-investigative approach to diagnosis of cutaneous hyperandrogenism in relation to adult female acne, female pattern alopecia & hirsutism a primer for dermatologists

Review

Author: Sehrawat, Manu ; Sardana, Kabir ; Khurana, Ananta ; Muddebihal, Aishwarya ; Bansal, Prekshi

INTRODUCTIONHyperandrogenism is a clinical state consequent to excess androgen production by the ovary, adrenals, or increased peripheral conversion of androgens. The varied manifestations of hyperandrogenism include seborrhea, acne, infertility, hirsutism, or overt virilization of which adult female acne, hirsutism, and female pattern hair loss are of clinical relevance to dermatologists.AREAS COVEREDWe limited our narrative review to literature published during period from 1 January 1985 to Dec 2022 and searched PubMed/MEDLINE, Web of Science (WOS), Scopus, and Embase databases with main search keywords were 'Hyperandrogenism,' 'Female,' 'Biochemical,' 'Dermatological', and 'Dermatology.' We detail the common etiological causes, nuances in interpretation of biochemical tests and imaging tools, followed by an algorithmic approach which can help avoid extensive tests and diagnose the common causes of hyperandrogenism.EXPERT OPINIONBased on current data, total testosterone, sex hormone binding globulin, DHEAS, prolactin, free androgen index, and peripheral androgenic metabolites like 3-alpha diol and androsterone glucuronide are ideal tests though not all are required in all patients. Abnormalities in these biochemical investigations may require radiological examination for further clarification. Total testosterone levels can help delineate broadly the varied causes of hyperandrogenism. Serum AMH could be used for defining PCOM in adults.

01 Feb 2024·Journal of the European Academy of Dermatology and Venereology

Female diffuse non‐cicatricial alopecia—The diagnostic value of trichoscopy

Letter

Author: Sechi, A. ; Sirtoli Marcondes, M. T. ; Iorizzo, M. ; Piraccini, B. M. ; Starace, M. ; Therianou, A.

31 Dec 2023·Journal of Dermatological Treatment

Use of autologous platelet-rich plasma in androgenetic alopecia in women: a systematic review and meta-analysis

Review

Author: Arcanjo, Francisco Plácido Nogueira ; de Oliveira, Antonio Flávio Queiroz ; Rodrigues, Maria Rosineida Paiva ; Hall, Peter Richard ; Rosa e Silva, Ana Augusta

OBJECTIVETo conduct a systematic review and meta-analysis to verify the efficacy of using autologous platelet-rich plasma (PRP) in female pattern alopecia (FPA).BACKGROUNDAndrogenetic alopecia is the leading cause of hair loss in men andwomen and often impacts self-esteem and quality of life.DATA SOURCESMEDLINE/PubMed, Cochrane Library, ClinicalTrials.gov, and EMBASE up to May 2021.STUDY SELECTION AND DATA EXTRACTIONWe identified all studies evaluating the effect of PRP in FPA. A narrative synthesis was performed from data on the efficacy of PRP treatment and adverse effects; quantitative results of PRP use compared to control treatment for female androgenetic alopecia (AGA) were synthesized. The outcomes analyzed were terminal density and hair thickness.RESULTSSeven articles were selected for this review. Meta-analysis showed that PRP-based interventions were able to increase terminal hair density compared to control (standardized mean difference (SMD)=2.98, 95% confidence intervals (CIs)=1.10, 4.85), with no significant increase in hair thickness (SMD = 1.16, 95% CI= -0.96, 3.28). During and after treatment, no major side effects were reported by patients or researchers.CONCLUSIONSThe use of autologous PRP injections in female AGA seems to be promising, with more consistent results on terminal hair density. However, caution is recommended in the interpretation of these results until they can be replicated in larger and more representative samples. PROSPERO registration number CRD42021257154.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Baldness, Female Pattern

Basic Info

Related

Analysis